SWOT Analysis
- S
- W
- O
- T
-
Strength (18)
Strong Momentum: Price above short, medium and long term moving averages
-
Weakness (3)
See all stocks where promoters decreased their stake. Promoters decreasing their shareholding in a stock is considered negative for the stock.
-
Opportunity (1)
FII / FPI or Institutions increasing their shareholding
-
Threats (1)
See all stocks where MFs decreased their stake last quarter. MFs decreasing their shareholding in a stock is considered negative for the stock.
- Strong Momentum: Price above short, medium and long term moving averages
- Rising Net Cash Flow and Cash from Operating activity
- Companies with high TTM EPS Growth
- New 52 week high today
- Good quarterly growth in the recent results
- Effectively using its capital to generate profit - RoCE improving in last 2 years
- Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
- Efficient in managing Assets to generate Profits - ROA improving since last 2 year
- Growth in Net Profit with increasing Profit Margin (QoQ)
- Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
- Companies with Low Debt
- Increasing Revenue every Quarter for the past 4 Quarters
- Increasing profits every quarter for the past 4 quarters
- Annual Net Profits improving for last 2 years
- Book Value per share Improving for last 2 years
- Recent Results : Growth in Operating Profit with increase in operating margins (YoY)
- Highest Recovery from 52 Week Low
- RSI indicating price strength
- FII / FPI or Institutions increasing their shareholding
Technical Analysis
Moving Averages
EMA
SMA
- 5 Day 1,939.4
- 10 Day 1,926.5
- 12 Day 1,921.1
- 20 Day 1,897.7
- 26 Day 1,877.6
- 50 Day 1,787.0
- 100 Day 1,616.4
- 200 Day 1,389.9
1,954.00
0.30%
Current Price
- Bullish Moving Averages 16
- Bearish Moving Averages 0
Resistance and support
1,963.33PIVOT
- First Resistance 1,972.7
- Second Resistance 1,991.3
- Third Resistance 2,000.7
- First Support 1,944.7
- Second Support 1,935.3
- Third Support 1,916.7
Company Financials
- Profit and loss statement
- Balance sheet
- Quarterly Result
- Ratio
- CAGR IN 10 YEARS
- 13.87%
- 16.44%
- 15.66%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| Sales | 6,089.07 | 5,216.98 | 4,812.39 | 5,773.45 | 4,707.04 |
|
| Operating Profit | 1,438.26 | 944.33 | 749.88 | 1,481.76 | 1,285.20 |
|
| OP Profit Margin | 23.62 | 18.10 | 15.58 | 25.67 | 27.30 |
|
| Interest | 142.96 | 182.20 | 150.82 | 145.70 | 95.86 |
|
| Profit After Tax | 740.48 | 380.39 | 223.70 | 760.38 | 750.09 |
|
| Cash Profit | 1,194.01 | 784.97 | 573.63 | 1,062.04 | 985.57 |
|
| EPS | 13.72 | 7.05 | 4.15 | 14.12 | 13.96 |
|
- CAGR IN 10 YEARS
- 16.24%
- 11.09%
- 16.29%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| Equity | 107.97 | 107.85 | 107.79 | 107.73 | 107.47 |
|
| Reserve Surplus | 5,143.97 | 4,456.10 | 4,099.26 | 3,949.09 | 3,280.74 |
|
| TOT Debts | 2,080.37 | 2,379.76 | 2,109.82 | 1,714.26 | 1,653.10 |
|
| Gross Block | 5,364.85 | 4,879.45 | 4,706.38 | 4,221.85 | 3,254.00 |
|
| Capital Work In Progress | 569.42 | 336.24 | 155.51 | 357.06 | 755.03 |
|
| Cash Liquid Investment | 37.82 | 50.64 | 42.92 | 1.70 | 40.56 |
|
| Net Working Capital | 2,727.94 | 2,727.72 | 2,281.20 | 2,108.91 | 1,774.17 |
|
| Current Assets | 4,461.38 | 4,082.86 | 3,570.73 | 3,216.32 | 3,286.20 |
|
| Current Liabilities | 1,733.44 | 1,355.14 | 1,289.53 | 1,107.41 | 1,512.03 |
|
Jun 2026 (CR) |
Mar 2026 (CR) |
Dec 2025 (CR) |
Sep 2025 (CR) |
Jun 2025 (CR) |
||
|---|---|---|---|---|---|---|
| Sales | 1,757.16 | 1,580.30 | 1,509.42 | 1,566.60 | 1,432.75 |
|
| Gross Profit | 483.93 | 354.54 | 328.75 | 384.43 | 305.01 |
|
| Gross Profit Margins | 55.75 | 52.04 | 56.96 | 58.87 | 60.01 |
|
| Operating Profit | 499.06 | 375.36 | 345.86 | 389.66 | 327.38 |
|
| OP Profit Margin | 24.09 | 18.56 | 17.62 | 20.59 | 17.82 |
|
| Interest | 35.20 | 33.91 | 31.48 | 33.68 | 43.89 |
|
| Profit After Tax | 289.96 | 191.79 | 175.08 | 215.67 | 157.94 |
|
| Cash Profit | 385.72 | 286.96 | 269.39 | 311.26 | 251.51 |
|
| EPS | 5.37 | 3.55 | 3.25 | 3.99 | 2.93 |
|
- CAGR IN 10 YEARS
- 16.24%
- 11.09%
- 16.29%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| PE | 72.31 | 87.01 | 94.39 | 20.76 | 42.27 |
|
| P/BV | 10.20 | 7.25 | 5.02 | 3.89 | 9.36 |
|
| MCAP Sales | 8.79 | 6.34 | 4.39 | 2.73 | 6.74 |
|
| Asset Turnover | 0.80 | 0.76 | 0.78 | 1.04 | 1.00 |
|
| EV/EBITDA | 36.68 | 33.91 | 29.07 | 11.68 | 25.50 |
|
| DEBT/EQUITY | 0.45 | 0.51 | 0.46 | 0.45 | 0.50 |
|
| ROE | 15.09 | 6.94 | 5.41 | 20.43 | 24.59 |
|
| ROCE | 14.95 | 9.14 | 7.34 | 21.62 | 22.71 |
|
Quick Results Snapshot
Q1FY27 Quarterly Result Announced for Laurus Labs Ltd.
Pharmaceuticals company Laurus Labs announced Q1FY27 results
Consolidated Financial Highlights:
- Total Revenue from operations for Q1FY27 stood at Rs 2,026.31 crore, reflecting a growth of 11.85% QoQ from Rs 1,811.57 crore in Q4FY26 and an increase of 29.10% YoY compared to Rs 1,569.57 crore in Q1FY26.
- Total Income for the quarter was Rs 2,035.49 crore, showing an 11.63% increase from Rs 1,823.37 crore in Q4FY26 and a 28.83% growth from Rs 1,580.00 crore in Q1FY26.
- Profit Before Tax (PBT) for Q1FY27 was reported at Rs 481.36 crore, marking a growth of 33.20% QoQ from Rs 361.37 crore in Q4FY26 and a substantial rise of 114.68% YoY from Rs 224.22 crore in Q1FY26.
- Net Profit for the period (after share of profit/loss from associates and joint venture) reached Rs 362.07 crore, representing a 28.35% QoQ increase from Rs 282.09 crore in Q4FY26 and a 123.94% YoY increase from Rs 161.68 crore in Q1FY26.
- Total Comprehensive Income for Q1FY27 was Rs 359.86 crore, compared to Rs 284.17 crore in Q4FY26 and Rs 160.97 crore in Q1FY26.
- Basic Earnings Per Share (EPS) for the quarter improved to Rs 6.81, up from Rs 5.17 in Q4FY26 and Rs 3.02 in Q1FY26.
Standalone Financial Highlights:
- Revenue from operations for Q1FY27 was Rs 1,757.16 crore, a growth of 11.19% QoQ from Rs 1,580.30 crore in Q4FY26 and a 22.64% YoY increase from Rs 1,432.75 crore in Q1FY26.
- Total Income for the quarter stood at Rs 1,777.23 crore, up 11.54% from Rs 1,593.39 crore in Q4FY26 and 22.21% from Rs 1,454.27 crore in Q1FY26.
- Profit Before Tax (PBT) reached Rs 388.17 crore in Q1FY27, reflecting an increase of 49.66% QoQ from Rs 259.37 crore in Q4FY26 and an 83.58% YoY growth from Rs 211.44 crore in Q1FY26.
- Net Profit for the period was Rs 289.96 crore, showing a significant QoQ growth of 51.19% from Rs 191.79 crore in Q4FY26 and an 83.59% YoY increase from Rs 157.94 crore in Q1FY26.
- Total Comprehensive Income for the standalone entity was Rs 288.15 crore in Q1FY27, compared to Rs 196.79 crore in Q4FY26 and Rs 157.75 crore in Q1FY26.
- Basic Earnings Per Share (EPS) for the standalone business was Rs 5.37 for Q1FY27, against Rs 3.55 in Q4FY26 and Rs 2.93 in Q1FY26.
Business Highlights:
- Scheme of Arrangement: The Board has approved a Composite Scheme of Arrangement for the demerger of the Identified Business Undertaking of Laurus Synthesis Private Limited into Sriam Labs Private Limited and the amalgamation of the Remaining Undertaking of Laurus Synthesis Private Limited with the Company. The implementation is subject to approvals from the NCLT and other authorities, with an appointed date of April 01, 2026.
- ESOP Allotment: During Q1FY27, the Company allotted 393,001 equity shares of Rs 2 each following the exercise of stock options by employees under the Employee Stock Option Scheme.
- Strategic Investments: The company previously invested Rs 35 crore into Laurus Bio Private Limited and contributed Rs 49 crore as capital to the KRKA Pharma Private Limited joint venture (49% stake) during the year ended March 31, 2026 (FY26).
- Subsidiary Performance: Six subsidiaries (including step-down subsidiaries) contributed a total revenue of Rs 177.14 crore and a total net loss after tax of Rs 5.96 crore to the consolidated results for Q1FY27.
Stocks Comparison
Table
Chart
Company name |
LTP |
Market cap (Cr) |
Return (1Y %) |
Risk (Std. Dev.) |
PE Ratio |
Financial Year |
|---|---|---|---|---|---|---|
| Laurus Labs Ltd | 1,954.00 | 105,577.01 | 118.58 | 0.11 | 96.89 | Mar 2026 |
| Sun Pharmaceutical Industries Ltd | 1,837.30 | 440,829.81 | 13.40 | 0.05 | 36.35 | Mar 2026 |
| Divis Laboratories Ltd | 9,375.00 | 248,876.79 | 54.92 | 0.11 | 85.02 | Mar 2026 |
| Torrent Pharmaceuticals Ltd | 4,840.00 | 184,098.04 | 36.40 | 0.04 | 84.76 | Mar 2026 |
| Zydus Lifesciences Ltd | 1,160.00 | 115,710.44 | 12.21 | 0.07 | 25.04 | Mar 2026 |
| Cipla Ltd | 1,394.50 | 112,655.86 | -10.59 | 0.06 | 33.02 | Mar 2026 |
| Aurobindo Pharma Ltd | 1,734.00 | 99,770.53 | 58.26 | 0.04 | 26.90 | Mar 2026 |
| Dr Reddys Laboratories Ltd | 1,185.00 | 98,909.61 | -9.64 | 0.06 | 30.71 | Mar 2026 |
| Lupin Ltd | 2,083.00 | 95,248.48 | 2.55 | 0.04 | 17.67 | Mar 2026 |
| Mankind Pharma Ltd | 2,300.70 | 95,029.28 | -10.49 | 0.06 | 46.30 | Mar 2026 |
| Glenmark Pharmaceuticals Ltd | 2,447.40 | 69,071.67 | 19.83 | 0.06 | 37.36 | Mar 2026 |
| Alkem Laboratories Ltd | 5,466.50 | 65,360.21 | -0.11 | 0.04 | 29.84 | Mar 2026 |
| Biocon Ltd | 385.00 | 62,743.22 | 8.65 | 0.08 | 150.39 | Mar 2026 |
| Abbott India Ltd | 27,270.00 | 57,948.75 | -11.95 | 0.05 | 35.89 | Mar 2026 |
| Anthem Biosciences Ltd | 928.50 | 52,305.97 | 7.40 | 0.09 | 91.36 | Mar 2026 |
| Ipca Laboratories Ltd | 2,009.60 | 50,984.40 | 53.26 | 0.07 | 37.10 | Mar 2026 |
| Gland Pharma Ltd | 2,961.90 | 48,874.56 | 49.07 | - | 43.30 | Mar 2026 |
| Glaxosmithkline Pharmaceuticals Ltd | 2,838.80 | 48,090.98 | 3.53 | 0.08 | 45.23 | Mar 2026 |
| Ajanta Pharma Ltd | 3,563.60 | 44,530.40 | 39.15 | 0.06 | 39.27 | Mar 2026 |
| J B Chemicals & Pharmaceuticals Ltd | 2,408.90 | 38,676.99 | 45.54 | 0.04 | 54.59 | Mar 2026 |
| Emcure Pharmaceuticals Ltd | 2,003.80 | 38,014.22 | 47.88 | 0.06 | 37.53 | Mar 2026 |
| Sai Life Sciences Ltd | 1,600.50 | 33,993.69 | 78.26 | 0.07 | 94.01 | Mar 2026 |
| Wockhardt Ltd | 2,086.10 | 33,897.49 | 34.74 | 0.17 | 81.91 | Mar 2026 |
| Neuland Laboratories Ltd | 22,840.00 | 29,303.47 | 41.37 | 0.12 | 58.96 | Mar 2026 |
| Acutaas Chemicals Ltd | 3,440.30 | 28,166.12 | 133.29 | 0.13 | 72.67 | Mar 2026 |
| Piramal Pharma Ltd | 208.16 | 27,713.34 | 2.48 | 0.10 | -88.14 | Mar 2026 |
| Granules India Ltd | 875.50 | 23,881.87 | 60.33 | 0.05 | 36.04 | Mar 2026 |
| Caplin Point Laboratories Ltd | 2,748.60 | 20,892.57 | 17.96 | 0.12 | 30.81 | Mar 2026 |
| Shilpa Medicare Ltd | 1,021.10 | 19,970.86 | 148.65 | 0.19 | 67.16 | Mar 2026 |
| ERIS Lifesciences Ltd | 1,321.30 | 18,311.01 | -19.85 | 0.05 | 27.50 | Mar 2026 |
| Pfizer Ltd | 4,002.40 | 18,310.07 | -23.07 | 0.06 | 24.90 | Mar 2026 |
| OneSource Specialty Pharma Ltd | 1,594.90 | 18,289.18 | -13.11 | 0.15 | -376.29 | Mar 2025 |
| Alivus Life Sciences Ltd | 1,430.80 | 17,566.14 | 52.37 | - | 29.13 | Mar 2026 |
| Jubilant Pharmova Ltd | 1,065.40 | 16,971.82 | -4.10 | 0.07 | 48.37 | Mar 2026 |
| Astrazeneca Pharma India Ltd | 6,751.50 | 16,878.75 | -26.12 | 0.07 | 99.50 | Mar 2026 |
| Cohance Lifesciences Ltd | 438.00 | 16,757.76 | -54.67 | - | 286.31 | Mar 2026 |
| Alembic Pharmaceuticals Ltd | 845.75 | 16,624.33 | -13.53 | 0.07 | 24.11 | Mar 2026 |
| Concord Biotech Ltd | 1,494.40 | 15,633.85 | -8.63 | - | 57.28 | Mar 2026 |
| Natco Pharma Ltd | 813.40 | 14,568.80 | -5.12 | 0.09 | 12.74 | Mar 2026 |
| Marksans Pharma Ltd | 320.15 | 14,508.04 | 78.62 | 0.14 | 27.81 | Mar 2026 |
| Strides Pharma Science Ltd | 1,219.80 | 11,243.23 | 37.79 | 0.07 | 17.72 | Mar 2026 |
| Viyash Scientific Ltd | 249.65 | 10,997.59 | 30.57 | 0.12 | 41.24 | Mar 2026 |
| Blue Jet Healthcare Ltd | 575.25 | 10,888.08 | -17.63 | 0.17 | 46.35 | Mar 2026 |
| Procter & Gamble Health Ltd | 5,503.50 | 9,135.47 | -13.42 | 0.08 | 25.59 | Mar 2026 |
| Aarti Pharmalabs Ltd | 820.40 | 7,439.37 | -10.67 | - | 34.91 | Mar 2026 |
| Sanofi India Ltd | 3,087.40 | 7,110.28 | -38.88 | 0.08 | 21.96 | Dec 2025 |
| Senores Pharmaceuticals Ltd | 1,402.60 | 6,459.48 | 103.50 | 0.10 | 49.48 | Mar 2025 |
| Jeena Sikho Lifecare Ltd | 510.40 | 6,344.31 | -39.09 | 0.11 | 26.81 | Mar 2026 |
Corporate Action
- Announcement
- Board Meeting
- Dividend
- Split
- Rights
- Events
Announcement under Regulation 30 (LODR)-Investor Presentation
Sep 18, 2026Please see attached enclosure.
Laurus Labs Limited - Analysts/Institutional Investor Meet/Con. Call Updates
Sep 15, 2026Laurus Labs Limited has informed the Exchange about Schedule of meet
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Sep 10, 2026Please see annexed enclosure.
Laurus Labs Limited - Analysts/Institutional Investor Meet/Con. Call Updates
Sep 10, 2026Laurus Labs Limited has informed the Exchange about Schedule of meet
Laurus Labs Limited - Analysts/Institutional Investor Meet/Con. Call Updates
Aug 31, 2026Laurus Labs Limited has informed the Exchange about Schedule of meet
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Aug 31, 2026Please see annexed enclosure.
| Ex-Date | Purpose | Notes |
|---|---|---|
| 2026-07-24 | Quarterly Results | |
| 2026-04-30 | Audited Results & Interim Dividend | |
| 2026-01-23 | Quarterly Results | |
| 2025-10-23 | Quarterly Results & Interim Dividend | |
| 2025-07-25 | Quarterly Results | |
| 2025-04-24 | Audited Results & Interim Dividend | |
| 2025-01-24 | Quarterly Results | |
| 2024-10-24 | Quarterly Results & Interim Dividend | |
| 2024-07-25 | Quarterly Results | |
| 2024-04-25 | Audited Results & Interim Dividend | |
| 2024-01-24 | Quarterly Results | |
| 2023-10-20 | Quarterly Results & Interim Dividend | |
| 2023-07-27 | Quarterly Results | |
| 2023-04-27 | Audited Results & 2nd Interim Dividend | |
| 2023-01-30 | Quarterly Results | |
| 2022-10-21 | Quarterly Results & Interim Dividend | |
| 2022-07-27 | Quarterly Results | |
| 2022-04-28 | Audited Results & Interim Dividend | |
| 2022-01-27 | Quarterly Results | |
| 2021-10-28 | Quarterly Results & Interim Dividend | |
| 2021-07-29 | Quarterly Results | |
| 2021-04-29 | Audited Results & 3rd Interim Dividend | |
| 2021-01-28 | Quarterly Results & Interim Dividend | |
| 2020-10-29 | Quarterly Results & Interim Dividend | |
| 2020-07-30 | Quarterly Results | |
| 2020-04-30 | Audited Results & Final Dividend | |
| 2020-03-12 | Interim Dividend | |
| 2020-01-30 | Quarterly Results | |
| 2019-10-31 | Quarterly Results | |
| 2019-08-02 | Quarterly Results | |
| 2019-05-02 | Audited Results & Dividend | |
| 2019-01-31 | Quarterly Results | |
| 2018-11-01 | Quarterly Results | |
| 2018-08-03 | Quarterly Results | |
| 2018-05-10 | Audited Results & Dividend | |
| 2018-01-29 | Quarterly Results | |
| 2017-11-09 | Quarterly Results | |
| 2017-08-10 | Quarterly Results | |
| 2017-05-18 | Audited Results & Dividend | |
| 2017-02-09 | Quarterly Results |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| 2026-05-08 | 1.2 | INTERIM | 2026-05-08 | Equity Share |
| 2025-10-31 | 0.8 | INTERIM | 2025-10-31 | Equity Share |
| 2025-05-09 | 0.8 | INTERIM | 2025-05-09 | Equity Share |
| 2024-11-06 | 0.4 | INTERIM | 2024-11-06 | Equity Share |
| 2024-05-08 | 0.4 | INTERIM | 2024-05-08 | Equity Share |
| 2023-11-02 | 0.4 | INTERIM | 2023-11-02 | Equity Share |
| 2023-05-10 | 1.2 | INTERIM | 2023-05-10 | Equity Share |
| 2022-11-03 | 0.8 | INTERIM | 2022-11-04 | Equity Share |
| 2022-05-10 | 1.2 | INTERIM | 2022-05-11 | Equity Share |
| 2021-11-17 | 0.8 | INTERIM | 2021-11-18 | Equity Share |
| 2021-05-11 | 0.8 | INTERIM | 2021-05-12 | Equity Share |
| 2021-02-08 | 0.4 | INTERIM | 2021-02-09 | Equity Share |
| 2020-11-10 | 0.8 | INTERIM | 2020-11-11 | Equity Share |
| 2020-07-01 | 1 | FINAL | Equity Share | |
| 2020-03-23 | 1.5 | INTERIM | 2020-03-25 | Equity Share |
| 2019-07-03 | 1.5 | FINAL | Equity Share | |
| 2018-06-28 | 1.5 | FINAL | Equity Share | |
| 2017-07-06 | 1.5 | FINAL | Equity Share |
| Ex-Date | Old FV | New FV | Record Date |
|---|---|---|---|
| 2020-09-29 | 10 | 2 | 2020-09-30 |
No Data Found
No Data Found
Insider & Institutional Activity
- Bulk Block Deals
- Insider Trading & SAST
Client name |
Deal Type |
Date |
Action |
Avg. price |
Quantity |
Exchange |
|---|---|---|---|---|---|---|
| Bnp Paribas Financial Markets | Bulk | 2026-08-31 |
Purchase |
1,860.35 | 15,399 | NSE |
| Integrated Core Strategies (Asia) Pte. Ltd. | Bulk | 2026-08-31 |
Purchase |
1,922.69 | 1,718 | NSE |
| Bnp Paribas Financial Markets | Bulk | 2026-08-31 |
Sell |
1,914.28 | 6,272,175 | NSE |
| Integrated Core Strategies (Asia) Pte. Ltd. | Bulk | 2026-08-31 |
Sell |
1,914.04 | 5,134,361 | NSE |
| Societe Generale | Bulk | 2026-08-31 |
Sell |
1,903.84 | 2,810,437 | NSE |
| Graviton Research Capital Llp | Bulk | 2025-01-27 |
Purchase |
536.50 | 3,690,709 | NSE |
| Graviton Research Capital Llp | Bulk | 2025-01-27 |
Sell |
536.23 | 3,689,009 | NSE |
| Arun Vijay Nathani | Block | 2023-03-14 |
Purchase |
305.00 | 635,894 | NSE |
| Cybage Software Private Limited | Block | 2023-03-14 |
Sell |
305.00 | 635,894 | NSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-11-14 |
Purchase |
455.40 | 529,337 | NSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-11-14 |
Sell |
455.40 | 529,337 | NSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-11-03 |
Purchase |
476.60 | 529,338 | NSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-11-03 |
Sell |
476.60 | 529,338 | NSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-10-25 |
Purchase |
479.80 | 284,783 | BSE |
| Ishares Msci India Small-Cap Etf | Block | 2022-10-25 |
Purchase |
479.80 | 210,010 | BSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-10-25 |
Sell |
479.80 | 284,783 | BSE |
| Ishares India Sc Mauritius Company | Block | 2022-10-25 |
Sell |
479.80 | 210,010 | BSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-10-17 |
Purchase |
516.10 | 447,533 | BSE |
| Ishares Msci India Small-Cap Etf | Block | 2022-10-17 |
Purchase |
516.10 | 69,957 | BSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-10-17 |
Sell |
516.10 | 447,533 | BSE |
| Ishares India Sc Mauritius Company | Block | 2022-10-17 |
Sell |
516.10 | 69,957 | BSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-10-11 |
Purchase |
516.60 | 437,620 | BSE |
| Ishares Msci India Small-Cap Etf | Block | 2022-10-11 |
Purchase |
516.60 | 68,408 | BSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-10-11 |
Sell |
516.60 | 437,620 | BSE |
| Ishares India Sc Mauritius Company | Block | 2022-10-11 |
Sell |
516.60 | 68,408 | BSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-10-03 |
Purchase |
513.00 | 437,878 | NSE |
| Ishares Msci India Small-Cap Etf | Block | 2022-10-03 |
Purchase |
513.00 | 68,448 | NSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-10-03 |
Sell |
513.00 | 437,878 | NSE |
| Ishares India Sc Mauritius Company | Block | 2022-10-03 |
Sell |
513.00 | 68,448 | NSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-09-19 |
Purchase |
516.75 | 297,665 | BSE |
| Ishares Msci India Small-Cap Etf | Block | 2022-09-19 |
Purchase |
516.75 | 46,159 | BSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-09-19 |
Sell |
516.75 | 297,665 | BSE |
| Ishares India Sc Mauritius Company | Block | 2022-09-19 |
Sell |
516.75 | 46,159 | BSE |
| Ishares Core Msci Total International Stock Etf | Block | 2022-05-04 |
Purchase |
593.35 | 371,403 | BSE |
| Ishares Core Total International Stock Mauritius Co | Block | 2022-05-04 |
Sell |
593.35 | 371,403 | BSE |
| Graviton Research Capital Llp | Bulk | 2020-08-03 |
Purchase |
1,011.41 | 643,600 | NSE |
| Graviton Research Capital Llp | Bulk | 2020-08-03 |
Sell |
1,011.48 | 643,600 | NSE |
| Setu Securities Pvt Ltd | Bulk | 2020-06-29 |
Purchase |
506.16 | 1,790,037 | BSE |
| Bnp Paribas Arbitrage | Bulk | 2020-06-29 |
Purchase |
504.25 | 1,500,000 | BSE |
| Avani Paresh Shah | Bulk | 2020-06-29 |
Purchase |
508.20 | 982,319 | BSE |
| Government Pension Fund Global | Bulk | 2020-06-29 |
Purchase |
504.00 | 941,732 | BSE |
| Mk Ventures | Bulk | 2020-06-29 |
Purchase |
504.89 | 758,000 | BSE |
| Millennium Stock Broking Pvt Ltd | Bulk | 2020-06-29 |
Purchase |
510.70 | 621,018 | BSE |
| Millennium Stock Broking Pvt Ltd | Bulk | 2020-06-29 |
Purchase |
513.21 | 52,448 | NSE |
| Avni Paresh Shah | Bulk | 2020-06-29 |
Purchase |
513.30 | 52,341 | NSE |
| Setu Securities Pvt Ltd | Bulk | 2020-06-29 |
Purchase |
519.76 | 50,317 | NSE |
| Bluewater Investment Ltd | Bulk | 2020-06-29 |
Sell |
506.07 | 12,489,596 | BSE |
| Setu Securities Pvt Ltd | Bulk | 2020-06-29 |
Sell |
512.06 | 1,572,343 | NSE |
| Avni Paresh Shah | Bulk | 2020-06-29 |
Sell |
511.76 | 936,470 | NSE |
| Millennium Stock Broking Pvt Ltd | Bulk | 2020-06-29 |
Sell |
510.95 | 608,360 | NSE |
| Setu Securities Pvt Ltd | Bulk | 2020-06-29 |
Sell |
506.92 | 268,011 | BSE |
| Avani Paresh Shah | Bulk | 2020-06-29 |
Sell |
509.99 | 98,190 | BSE |
| Millennium Stock Broking Pvt Ltd | Bulk | 2020-06-29 |
Sell |
513.88 | 65,106 | BSE |
| Prb Securities Pvt. Ltd. | Bulk | 2020-05-08 |
Purchase |
449.47 | 1,031,793 | BSE |
| Millennium Stock Broking Pvt Ltd | Bulk | 2020-05-08 |
Purchase |
448.87 | 927,164 | BSE |
| Graviton Research Capital Llp | Bulk | 2020-05-08 |
Purchase |
450.69 | 612,646 | NSE |
| N.K.Securities | Bulk | 2020-05-08 |
Purchase |
450.16 | 579,626 | NSE |
| Elixir Wealth Management Private Limited | Bulk | 2020-05-08 |
Purchase |
449.54 | 349,887 | NSE |
| Setu Securities Pvt Ltd | Bulk | 2020-05-08 |
Purchase |
451.59 | 311,585 | NSE |
| Millennium Stock Broking Pvt Ltd | Bulk | 2020-05-08 |
Purchase |
449.36 | 159,460 | NSE |
| Prb Securities Pvt Ltd | Bulk | 2020-05-08 |
Purchase |
449.85 | 131,714 | NSE |
| Bluewater Investment Ltd | Bulk | 2020-05-08 |
Sell |
441.26 | 8,500,000 | BSE |
| Eight Roads Management Mauritius I Limited | Bulk | 2020-05-08 |
Sell |
446.07 | 5,331,375 | BSE |
| Prb Securities Pvt Ltd | Bulk | 2020-05-08 |
Sell |
449.64 | 1,033,109 | NSE |
| Millennium Stock Broking Pvt Ltd | Bulk | 2020-05-08 |
Sell |
449.10 | 919,976 | NSE |
| Setu Securities Pvt Ltd | Bulk | 2020-05-08 |
Sell |
450.77 | 657,106 | NSE |
| Graviton Research Capital Llp | Bulk | 2020-05-08 |
Sell |
450.61 | 612,646 | NSE |
| N.K.Securities | Bulk | 2020-05-08 |
Sell |
450.42 | 579,626 | NSE |
| Elixir Wealth Management Private Limited | Bulk | 2020-05-08 |
Sell |
449.12 | 563,229 | NSE |
| Millennium Stock Broking Pvt Ltd | Bulk | 2020-05-08 |
Sell |
449.88 | 166,648 | BSE |
| Prb Securities Pvt. Ltd. | Bulk | 2020-05-08 |
Sell |
449.93 | 129,373 | BSE |
| Amansa Holdings Private Limited | Bulk | 2019-03-14 |
Purchase |
351.00 | 3,300,000 | BSE |
| Fil Capital Management (Mauritius) Limited | Bulk | 2019-03-14 |
Sell |
351.15 | 6,118,806 | BSE |
| Amansa Holdings Private Limited | Bulk | 2019-03-08 |
Purchase |
350.00 | 1,209,249 | NSE |
| Amansa Holdings Private Limited | Bulk | 2019-03-08 |
Purchase |
350.00 | 1,018,308 | BSE |
| Nagarani Chava | Bulk | 2018-08-10 |
Purchase |
444.99 | 570,000 | NSE |
| Satyanarayana Chava | Bulk | 2018-05-25 |
Purchase |
453.99 | 633,104 | NSE |
| Norges Bank On Account Of Government Pension Fund | Bulk | 2018-04-23 |
Purchase |
508.00 | 1,750,000 | BSE |
| Nomura India Investment Fund Mother Fund | Bulk | 2018-04-23 |
Sell |
508.00 | 1,754,008 | BSE |
| Morgan Stanley Investment Funds Indian Equity Fund | Bulk | 2017-06-23 |
Purchase |
607.05 | 563,543 | BSE |
| Local Goverment Superannuation Scheme | Bulk | 2017-06-23 |
Sell |
607.05 | 563,543 | BSE |
| Norges Bank On Account Of The Government Pension Fund Global | Bulk | 2017-04-07 |
Sell |
502.55 | 567,414 | BSE |
| Nomura India Investment Fund Mother Fund | Bulk | 2016-12-19 |
Purchase |
477.56 | 735,000 | NSE |
Client name |
Client Category |
Action |
Reported to Exchange |
Quantity |
Post Transaction Holding |
Avg. Price |
Regulation (Insider/SAST) |
Mode |
|---|---|---|---|---|---|---|---|---|
| Mirae Asset Mutual Fund | Other |
Acquisition |
2026-03-05 | 111,064 | 21,737,464 | SAST 29(2) | Market | |
| Mirae Asset Mutual Fund | Other |
Acquisition |
2025-08-01 | 858,801 | 10,958,934 | SAST 29(2) | Market | |
| Mirae Asset Mutual Fund | Other |
Disposal |
2025-02-01 | 299,750 | 2,934 | SAST 29(2) | Market | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 790,000 | 2,790,000 | SAST Reg31 | Creation | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 1,000,000 | 2,000,000 | SAST Reg31 | Creation | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 1,000,000 | 1,000,000 | SAST Reg31 | Creation | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 3,450,000 | 6,240,000 | SAST Reg31 | Creation | |
| Satyanaryana Chava | Promoter |
Pledge |
2024-12-24 | 3,450,000 | 6,240,000 | SAST Reg31 | Creation | |
| Chava Naga Rani | Promoter |
Pledge |
2024-12-24 | 800,000 | 800,000 | SAST Reg31 | Creation | |
| Chava Naga Rani | Promoter |
Pledge |
2024-12-24 | 1,300,000 | 2,100,000 | SAST Reg31 | Creation | |
| Dr. Raju Srihari Kalidindi | Promoter |
Pledge |
2024-12-24 | 600,000 | 600,000 | SAST Reg31 | Creation | |
| Naga Rani Chava | Promoter |
Pledge |
2024-12-24 | 700,000 | 2,800,000 | SAST Reg31 | Creation | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 1,500,000 | 7,740,000 | SAST Reg31 | Creation | |
| Dr Raju Srihari Kalidindi | Promoter |
Pledge |
2024-12-24 | 600,000 | 0 | SAST Reg31 | Release | |
| Chava Naga Rani | Promoter |
Pledge |
2024-12-24 | 450,000 | 3,250,000 | SAST Reg31 | Creation | |
| Chunduru Venkata Lakshmana Rao | Promoter |
Pledge |
2024-12-24 | 100,000 | 100,000 | SAST Reg31 | Creation | |
| Chunduru Venkata Lakshman Rao | Promoter |
Pledge |
2024-12-24 | 90,000 | 190,000 | SAST Reg31 | Creation | |
| Chunduru Venkas Lakshmana Rao | Promoter |
Pledge |
2024-12-24 | 60,000 | 250,000 | SAST Reg31 | Creation | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 2,750,000 | 10,490,000 | SAST Reg31 | Creation | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 2,000,000 | 11,740,000 | SAST Reg31 | Creation | |
| Chava Naga Rani | Promoter |
Pledge |
2024-12-24 | 1,750,000 | 1,500,000 | SAST Reg31 | Release | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 2,900,000 | 8,840,000 | SAST Reg31 | Release | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 2,500,000 | 8,840,000 | SAST Reg31 | Release | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 2,500,000 | 11,340,000 | SAST Reg31 | Creation | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 500,000 | 8,340,000 | SAST Reg31 | Release | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 2,500,000 | 5,840,000 | SAST Reg31 | Release | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 1,500,000 | 6,840,000 | SAST Reg31 | Creation | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 1,560,000 | 5,280,000 | SAST Reg31 | Release | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 500,000 | 5,340,000 | SAST Reg31 | Release | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 650,000 | 4,630,000 | SAST Reg31 | Release | |
| Nagarani Chava | Promoter |
Pledge |
2024-12-24 | 750,000 | 750,000 | SAST Reg31 | Release | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 225,000 | 4,405,000 | SAST Reg31 | Release | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 1,100,000 | 19,175,000 | SAST Reg31 | Release | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 1,750,000 | 20,275,000 | SAST Reg31 | Release | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 1,100,000 | 20,275,000 | SAST Reg31 | Creation | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 2,200,000 | 18,075,000 | SAST Reg31 | Release | |
| Nagarani Chava | Promoter |
Pledge |
2024-12-24 | 3,750,000 | 0 | SAST Reg31 | Release | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 5,750,000 | 0 | SAST Reg31 | Release | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 6,575,000 | 11,500,000 | SAST Reg31 | Release | |
| Satyanarayana Chava | Promoter |
Pledge |
2024-12-24 | 5,750,000 | 5,750,000 | SAST Reg31 | Release | |
| Chunduru Venkata Lakshmana Rao | Promoter |
Pledge |
2024-12-24 | 800,000 | 1,700,000 | SAST Reg31 | Release | |
| Chunduru Venkata Lakshmana Rao | Promoter |
Pledge |
2024-12-24 | 1,700,000 | 0 | SAST Reg31 | Release | |
| Prathima Chava | Connected Person |
Pledge |
2024-12-10 | 200,000 | 433,875 | 576.40 | Insider Trading | Creation Of Pledge |
| Mirae Asset Mutual Fund | Other |
Disposal |
2024-09-05 | 93,294 | 5,133,145 | SAST 29(2) | Market | |
| Mirae Asset Mutual Fund | Other |
Disposal |
2024-08-08 | 1,101,072 | 15,875,789 | SAST 29(2) | Market | |
| Mirae Asset Mutual Fund | Other |
Acquisition |
2024-06-25 | 424,675 | 27,399,507 | SAST 29(1) | Market | |
| Mrs. G. Sreelakshmi | Employees Immediate Relative |
Disposal |
2023-10-30 | 10,000 | 11,000 | 376.00 | Insider Trading | Market Sale |
| New World Fund, Inc. | Acquisition |
2022-08-23 | 563,196 | 27,081,688 | SAST 29(1) | Market | ||
| Venkata Jayasree Kumari Tadikonda | Employees Immediate Relative |
Acquisition |
2022-03-24 | 788 | 17,688 | 578.70 | Insider Trading | Market Purchase |
| Venkata Jayasree Kumari Tadikonda | Employees Immediate Relative |
Acquisition |
2022-03-24 | 3,992 | 16,900 | 578.70 | Insider Trading | Market Purchase |
| Venkata Jayasree Kumari Tadikonda | Employees Immediate Relative |
Acquisition |
2022-03-24 | 2,906 | 12,908 | 578.70 | Insider Trading | Market Purchase |
| Madhuri Medasani | Employees Immediate Relative |
Acquisition |
2022-03-01 | 10,000 | 10,225 | 539.67 | Insider Trading | Market Purchase |
| Yamini Tanguturi | Employees Immediate Relative |
Disposal |
2022-03-01 | 2,275 | 0 | 525.95 | Insider Trading | Market Sale |
| Chandra Kumari | Employees Immediate Relative |
Pledge |
2021-12-18 | 10,245 | 10,245 | 505.00 | Insider Trading | Creation Of Pledge |
| Nsn Holdings | Promoter |
Acquisition |
2021-11-18 | 124,126,740 | 124,126,740 | SAST 29(1) | Off Market / Inter se transfer | |
| Nagarani Chava | Promoter |
Disposal |
2021-11-18 | 35,132,720 | SAST 29(2) | Off Market / Inter se transfer | ||
| Dr Satyanarayana Chava | Promoter |
Disposal |
2021-11-18 | 88,994,020 | SAST 29(2) | Off Market / Inter se transfer | ||
| Nsn Holdings | Other |
Acquisition |
2021-11-15 | 124,126,740 | SAST 10(6) | - | ||
| Nsn Holdings | Other |
Acquisition |
2021-11-08 | 124,126,740 | SAST 10(1)(a) |
About Laurus Labs Ltd
Stock PE (TTM)
96.89
Promoter Holding
27.47%
Book Value
98.0943
ROCE
16.7%
ROE
18.21%
Laurus Labs Ltd is in the Pharmaceuticals sector with the Market Capitalization of worth Rs. 37508.48 crores, it is incorporated in the year 2005. It features consolidated sales of Rs. 1220.60 crores in June 2021. The company is also listed in the Bombay Stock Exchange (BSE) with the code 540222 and additionally listed in the National Stock Exchange (NSE) with the code LAURUSLABS.
Laurus Labs is one of the top pharmaceuticals companies in the country, holding a leadership position in research & development and manufacturing of generic APIs. The company is also working with several top pharmaceuticals companies worldwide for research & development with a primary focus on anti-retroviral, Hepatitis C, and Oncology drugs. The company also owns around 155 patents. The headquarters of Laurus labs are situated in the city of Hyderabad, while its manufacturing plants are located in Visakhapatnam, Hyderabad, and Bengaluru. Laurus Labs has also received several approvals from major regulatory medical bodies worldwide, such as WHO, USFDA, KFDA, MHRA, etc. In March’20, Laurus Labs received approval from USFDA for hydroxychloroquine tablets, which were initially used to treat the COVID-19 patients. The promoters within the company currently hold 53.56% of the stake in the company, while the Foreign Institutional Investors (FII) and Domestic Institutional Investors (DII) hold 6.65% and 3.44% of the stake. The balance of 36.35% is by others (retail investors).
In June 2021, quarterly net sales were Rs. 1,220.6 crores, which has increased by approximately 25.78% from Rs. 970.4 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 222.08 crores, which has grown by 39.87% from a net profit of Rs. 158.78 crores in June 2020. In June 2021, operating profit was reported at Rs. 1,032.11 crores, which is also increased by 25.79% as compared to an operating profit of Rs. 820.49 crores for the quarter ending in June 2020. From Rs. 2.97 in June 2020, the EPS of Laurus Labs has grown to just Rs. 4.14 per share in June 2021. LAURUSLABS’s stock closed at Rs. 689.35 on 16th August’2021 (NSE) and has returned 86.97% in the last six months and 234.49% within the last year.
Laurus Labs share price as on 20 Sep 2026 is Rs. 1954. Over the past 6 months, the Laurus Labs share price has increased by 101.71% and in the last one year, it has increased by 118.58%. The 52-week low for Laurus Labs share price was Rs. 823.1 and 52-week high was Rs. 1982.
Registered Office
Plot No 21 Jawaharlal Nehru, Pharma City Parawada, Visakhapatnam, Andhra Pradesh, 531021
Tel No. 91-891-3061222
Email secretarial:lauruslabs.com; info:lauruslabs.com
Registrars
Management
Independent Director
Executive Director
Independent Non Exe. Director
Independent Non Exe. Director
Chairman & Independent Directo
CS / Compliance Officer / Vice President - Legal
Executive Director & CEO
Executive Director
Executive Director
Independent Non Exe. Director
Independent Director
Executive Director & CFO
Listing Info
540222
LAURUSLABS
INE947Q01028
Jul
Laurus Labs Ltd FAQs
You can buy Laurus Labs Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Laurus Labs Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Sep 18, 2026 03:59 PM the closing price of Laurus Labs Ltd was Rs.1,954.00.
The latest PE ratio of Laurus Labs Ltd as of Sep 18, 2026 03:59 PM is 96.89
The latest PB ratio of Laurus Labs Ltd as of Sep 18, 2026 03:59 PM is 19.92
The 52-week high of Laurus Labs Ltd share price is Rs. 1,982.00 while the 52-week low is Rs. 823.10
According to analyst recommendations, Laurus Labs Ltd Share has a "Buy" rating for the long term.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Sep 18, 2026 03:59 PM, the market cap of Laurus Labs Ltd stood at Rs. 105,564.85 Cr.
Market Outlook
View allNo news to display.
